• UCLA Health
  • myUCLAhealth
  • School of Medicine
Institute of Urologic Oncology

UCLA Institute of Urologic Oncology

Institute of Urologic Oncology
  • About Us
    • Director's Welcome
    • Board of Directors
    • IUO in the News
    • Why Choose the UCLA IUO
    • Support the IUO
    • Contact Us
    • The Wasserman Building
    • Maps and Directions
    • IUO Membership Information
    • Administrative & Research Staff
    • Positions Available
  • Clinical Programs
    • Bladder Cancer
    • Kidney Cancer
    • Prostate Cancer
    • Testicular Cancer
    • Integrated Cancer Program
    • Cancer Genetic Risk Assessment Program
    • Second Opinion for Cancer
  • Research Programs
    • Clinical Trials
    • Faculty Labs
    • Bladder Cancer
    • Kidney Cancer
    • Prostate Cancer
    • PSMA Risk Calculator
    • SPORE In Prostate Cancer
    • External Funding Opportunities
    • Webinars / Videos
  • Clinical Trials
    • What Is a Clinical Trial?
    • Who Should Consider Clinical Trials & Why
    • Bladder Cancer Clinical Trials
    • Kidney Cancer Clinical Trials
    • Prostate Cancer Clinical Trials
    • Clinical Research Team
    • IUO Membership Study Information
  • For Patients
    • Contact Us
    • Clinical Updates
    • Health Plans and Financial Matters
    • Maps and Directions
    • myUCLAhealth
    • Patient Testimonials
    • Preparing for Surgery
    • Webinars / Videos
  • Fellowship
    • Current Fellows
    • Former Fellows
    • Fellow Testimonials
    • UCLA Health Aerial Tour
  • For Healthcare Professionals
    • How to Refer a Patient
    • Lectures & Conferences
    • CTSI Distinguished Speaker Seminar Series
    • DGSOM Research Seminars
    • DGSOM Events
    • JCCC Seminars
    • SPORE Lectures
    • External Funding Opportunities
  • Expert Team
    • Board of Directors
    • Medical Oncology
    • Nuclear Medicine
    • Pathology
    • Radiation Oncology
    • Radiology
    • Urologic Oncology
    • Research Faculty
    • Emeritus Faculty
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

UCLA Institute of Urologic Oncology

Clinical Trials

Clinical Trials

Clinical Trials

  • What Is a Clinical Trial?
  • Who Should Consider Clinical Trials & Why
  • Bladder Cancer Clinical Trials
  • Kidney Cancer Clinical Trials
  • Prostate Cancer Clinical Trials
  • Clinical Research Team
  • IUO Membership Study Information
  • What Is a Clinical Trial?
  • Who Should Consider Clinical Trials & Why
  • Bladder Cancer Clinical Trials
  • Kidney Cancer Clinical Trials
  • Prostate Cancer Clinical Trials
  • Clinical Research Team
  • IUO Membership Study Information
  1. Home
  2. Institute of Urologic Oncology
  3. Clinical Trials
  4. Short-Course Radiotherapy After Removal of Prostate

Short-Course Radiotherapy After Removal of Prostate

Share this

Short-Course Radiotherapy After Removal of Prostate

Technical Title: SCIMITAR (StereotaCtic Intensity Modulated RadIoTherapy After Radical Prostatectomy)

Disease Type: Prostate cancer

Basic information:
This study researches the effectiveness of a short course of radiation after surgery for treatment of prostate cancer. 

Men with advanced prostate cancer often undergo a total removal of their prostate, followed by external beam radiation delivered in a schedule whereby the total dose is spread out over many small, separate doses, or “fractions,” typically over a period of weeks. This is referred to as Intensity Modulated Radiotherapy, or “IMRT.”

This study will examine the effectiveness and safety of Stereotactic Body Radiotherapy, “SBRT,” which delivers the same total dose of radiation given over only five separate fractions over about a five day period. While SBRT is commonly used for the treatment of prostate cancer, it is considered experimental in patients who have undergone the removal of their prostate. This study is designed to discover whether SBRT is safe in men with advanced prostate cancer who have had their prostates removed, and whether it helps them lead longer, healthier lives than those patients who receive IMRT after removal of their prostate.

Research Procedures:

Following the surgical removal of the prostate, study patients will come to Radiation Oncology for a treatment planning session which requires a CT scan, then return about one week later to receive radiation to the pelvis on five separate occasions over about a one week period.  Patients will return to Radiation Oncology for regular follow-up visits for at least one year, but may be asked to allow follow-up information to be gathered from other doctors for up to five years.  At four different occasions, patients will be asked to provide blood samples solely for the purposes of long-term scientific research. 

Eligibility Criteria (not a complete list):
Inclusion Criteria:

  • Must have had a radical prostatectomy
  • Must have certain pathology results or tests which may indicate a possible return of your cancer

Exclusion Criteria:

  • May not have metastatic disease
  • May not have already undergone any radiation therapy for prostate cancer

For More Detailed Information, Contact:

  • Amir Kishan, MD, Principal Investigator, 310-825-9771
  • Ankush Sachdeva, Study Coordinator, 310-267-8996
  • UCLA Department of Radiation Oncology
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest
UCLA Health hospitals ranked best hospitals by U.S. News & World Report
  • UCLA Health
  • Find a Doctor
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Subscribe
  • Patient Stories
  • Giving
  • Careers
  • Volunteer
  • International Services
  • Privacy Practices
  • Nondiscrimination
  • Billing
  • Health Plans
  • Emergency
  • Report Broken Links
  • Terms of Use
  • 1-310-825-2631
  • Maps & Directions
  • Contact Us
  • Your Feedback
  • Report Misconduct
  • Get Social
  • Sitemap
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest